Prospective, Single Center, Pilot Study of Pretransplant Thymoglobulin Administration and Early Corticosteroid Withdrawal in Living Donor Renal Transplant Recipients Under Mycophenolate Mofetil (MMF) and Tacrolimus Maintenance Immunosuppression
We will evaluate the therapeutic efficacy of administering Thymoglobulin® induction
pre-transplantation in renal allograft recipients. Patients receiving pre-transplant
Thymoglobulin will be evaluated for acute rejection (Banff '97 criteria), survival, and
safety at 6 months. Overall the use of Thymoglobulin induction pre-transplantation will be
safe and effective.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Composite end point of acute rejection, graft survival or patient survival
6 months
No
E. Steve Woodle, MD
Principal Investigator
University of Cincinnati
United States: Institutional Review Board
Pre-Tx Thymo
NCT00771745
September 2008
July 2010
Name | Location |
---|---|
The Christ Hospital | Cincinnati, Ohio 45219 |